Biohaven Ltd. (BHVN)
After hours:
| Previous close | 38.99 |
| Open | 39.70 |
| Bid | 0.00 x 1000 |
| Ask | 0.00 x 1100 |
| Day's range | 38.19 - 39.70 |
| 52-week range | 12.35 - 62.21 |
| Volume | |
| Avg. volume | 1,267,638 |
| Market cap | 3.383B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.73 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 59.50 |
PR NewswireBiohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share. The gross proceeds from t
- PR Newswire
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public
- PR Newswire
Biohaven Announces Proposed Public Offering of Common Shares
Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an
